PF-04383119 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 226 | Interstitial cystitis with Hunners ulcer | 7 |
226. Interstitial cystitis with Hunners ulcer
Clinical trials : 143 / Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-014597-17-SE (EUCTR) | 03/05/2010 | 28/10/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Spain;Belgium;Germany;Sweden | ||
| 2 | EUCTR2009-014597-17-FI (EUCTR) | 24/03/2010 | 04/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 3 | EUCTR2009-014597-17-DE (EUCTR) | 19/03/2010 | 03/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 4 | EUCTR2009-014597-17-ES (EUCTR) | 08/02/2010 | 12/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Finland;Belgium;Spain;Germany;Sweden | ||
| 5 | EUCTR2009-014597-17-SK (EUCTR) | 03/02/2010 | 11/02/2010 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| 6 | EUCTR2009-014597-17-BE (EUCTR) | 24/12/2009 | 09/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 2 | Finland;Germany;Belgium;Spain;Sweden | ||
| 7 | NCT00601484 (ClinicalTrials.gov) | March 2008 | 15/1/2008 | An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis | A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial Cystitis | Cystitis, Interstitial | Drug: PF-04383119;Drug: Placebo | Pfizer | NULL | Completed | 18 Years | N/A | Both | 65 | Phase 2 | United States |